One of these pairings has 3,400 people behind it.
Cagrilintide plus tirzepatide vs CagriSema sounds like a fair fight. Both stack an amylin analogue on top of an incretin drug. Both are being run by people who want more than semaglutide or tirzepatide alone can give. The difference is that one pairing went through a phase 3 programme and is sitting at the FDA, and the other has never been given to a single human in a trial. That does not make the second one wrong. It makes it a bet, and you should know the odds before you place it.
🔑 Key Takeaways
- CagriSema is a defined product with phase 3 data. Cagrilintide plus tirzepatide is a community stack with none.
- Tirzepatide alone already beats CagriSema. That reframes the whole question.
- Amylin stacks sub-additively on top of an incretin. Adding cagrilintide to semaglutide gained 5.5 points, not the 11.5 cagrilintide produces alone.
- Whether that gain carries over to tirzepatide, which already hits two incretin receptors, is a hypothesis with one short study outside humans to support it.
- The decision comes down to what you are already on. The section on who each stack suits spells it out.
For the pieces individually, see the cagrilintide guide, the tirzepatide guide, and the CagriSema guide. For the two-drug protocol details, see the tirzepatide and cagrilintide stack page.
Cagrilintide + Tirzepatide vs CagriSema at a Glance
Why Amylin Gets Added to Incretins at All
Different door, same room.
GLP-1 and GIP are gut hormones. Amylin comes from the pancreas alongside insulin. All three reduce appetite and slow gastric emptying, but amylin does it through its own receptors and the calcitonin receptor in the brainstem rather than through incretin receptors. That separate pathway is why Novo Nordisk built cagrilintide to sit on top of semaglutide: two signals should beat one.
They do, but not by as much as arithmetic suggests. In REDEFINE 1, semaglutide alone produced 14.9% weight loss and cagrilintide alone produced 11.5%. Together they produced 20.4%, not 26.4%. The pathways converge on the same appetite circuits, so the second drug adds less than it would on its own. That 5.5-point gain is real and commercially decisive, and it is also the ceiling you should have in mind when thinking about adding cagrilintide to anything. The cagrilintide vs semaglutide comparison goes through the monotherapy arms in detail.
What CagriSema Actually Showed
Strong, and still a disappointment.
REDEFINE 1 delivered 20.4% at 68 weeks on the treatment-policy estimand and 22.7% on the trial-product estimand. Novo had publicly guided to 25%, and the miss cost the company roughly $72 billion in market value in a day. REDEFINE 2, in people with type 2 diabetes, showed 13.7%, ahead of semaglutide alone. Then REDEFINE 4 ran CagriSema directly against tirzepatide 15 mg over 84 weeks. Tirzepatide won: 25.5% against 23.0%.
That last trial is the one that matters for this comparison. The best-evidenced amylin-plus-incretin combination in existence lost, head to head, to tirzepatide on its own. Anyone already on tirzepatide is already ahead of CagriSema. The question is whether adding cagrilintide moves them further ahead, and nobody has measured it.
What Cagrilintide + Tirzepatide Has Behind It
One short study, not in humans.
A registry search returns dozens of cagrilintide trials. The only ones that mention tirzepatide use it as the comparator arm against CagriSema. No trial has given people both cagrilintide and tirzepatide. The single piece of direct evidence is a 12-day study in animals presented as a conference abstract: at 3 nmol/kg of each, the combination produced around 11% weight loss against 7.2% for cagrilintide alone and 2.5% for tirzepatide alone. That points in the expected direction and tells you almost nothing about a 70 kg human over six months.
The mechanistic argument is reasonable. Tirzepatide hits GIP and GLP-1 receptors. Cagrilintide hits amylin and calcitonin receptors. There is no receptor overlap, so some additive effect is plausible. The counter-argument is the same one REDEFINE 1 taught: appetite pathways converge downstream, and tirzepatide's dual agonism may already be occupying more of the available appetite suppression than semaglutide did. The gain from adding amylin on top could be smaller than 5.5 points. It could also be larger. Nobody knows, and that uncertainty is the product you are buying.
Dosing the Two Stacks
One is on a label. One is on forums.
CagriSema titrates both molecules in parallel to 2.4 mg each over 16 weeks, then holds. The steps follow the Wegovy schedule: 0.25, 0.5, 1.0, 1.7, 2.4 mg, four weeks each. That is the protocol the phase 3 data describes, and it is what the semaglutide and cagrilintide stack guide reconstructs for vial users.
Cagrilintide + tirzepatide has no reference schedule. The community approach borrows from each drug's own titration: tirzepatide from 2.5 mg weekly up to 10 or 15 mg over 16 to 20 weeks, cagrilintide from 0.25 mg weekly up to 2.4 mg over a similar window. Most people who have written up their protocol stabilise on tirzepatide first, then layer cagrilintide in at the low end and hold for longer than they would alone, because the GI effects of three appetite pathways at once are the limiting factor. The stack guide sets out the sequencing in full.
Side Effects: The Same Problem, Amplified
Nausea does not care which incretin you chose.
In REDEFINE 1, about four in five people on CagriSema reported a gastrointestinal adverse event, mostly nausea, constipation and vomiting concentrated during titration. Discontinuation for adverse events was higher than on semaglutide alone. That is the measured cost of one amylin plus one incretin.
Tirzepatide's own GI profile is similar to semaglutide's, with SURMOUNT-1 reporting nausea in around a third of people at the higher doses. Stack cagrilintide on top and the reasonable expectation is a GI burden at least equal to CagriSema's, possibly higher, with no trial to tell you what to expect or when it settles. Injection-site reactions, more common with cagrilintide than with either incretin, come along regardless of the pairing. See the cagrilintide side effects guide for what the trials recorded.
Which Stack Should You Choose?
Start from where you are.
Choose CagriSema-style dosing if you are on semaglutide and have plateaued, you want a combination with phase 3 data behind every number, or you would rather wait for a prescribable pen than manage two vials. This is the pairing the evidence supports.
Consider cagrilintide + tirzepatide if you are already on tirzepatide at a stable dose, you have plateaued there, and you accept that you are running an unstudied combination on mechanism alone. The upside is that you start from a stronger base than CagriSema does. The downside is that every dose decision is a guess.
Do not switch from tirzepatide to CagriSema in the expectation of losing more. REDEFINE 4 says you would lose less. If you are on tirzepatide and want more, the honest options are a higher tirzepatide dose, more time, or the unstudied stack, in that order of evidence.
Frequently Asked Questions
The Verdict
CagriSema is the evidence. Cagri + tirz is the bet.
If you want the amylin-plus-incretin pairing that has been through phase 3, it is CagriSema, and it is likely to be prescribable soon. If you are already on tirzepatide, you have already passed CagriSema's result and the only remaining question is whether a third pathway adds anything. That is a reasonable hypothesis with no human data, which means you would be the trial. Some people are comfortable with that. Go in knowing it, rather than believing the stack has evidence it does not.
References
- Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med 2025. NEJM
- Davies MJ, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med 2025. NEJM
- ClinicalTrials.gov NCT06131437. A research study to see how well CagriSema compared to tirzepatide helps people with obesity lose weight (REDEFINE 4). ClinicalTrials.gov
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387(3):205-216. PubMed
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: phase 2 trial. Lancet 2021;398(10317):2160-2172. PubMed
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new supplement, medication, or treatment. PeptideDeck may earn a commission from affiliate links at no additional cost to you.